{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:28:00Z","timestamp":1788348480238,"version":"build-2803163510"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the effect and side effects of topical 2% rebamipide ophthalmic suspension in dry eye disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>This prospective randomized case control study included total 80 patients (40 cases and 40 controls) of dry eye. Symptoms were graded according to OSDI scoring system and specific tests for dry eye included Tear film breakup time (TBUT), Schirmer\u2019s test, Fluorescein corneal staining (FCS), Rose Bengal staining) were performed. Case group received 2% rebamipide ophthalmic suspension four times daily and control group given carboxymethylcellulose 0.5% four times daily. The follow ups had done at two, six and twelve weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The maximum numbers of patients were between 45-60 years. Patient with mild moderate and severe OSDI Score shows marked improvement. Mild TBUT score showed improvement but statistically not significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value-0.34). In moderate and severe TBUT Score statistically significant improvement (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value- 0.0001, 0.0001). In all grade FCS shows statistically significant improvement with p value-0.0001, 0.0001, and 0.028 respectively. Schirmer\u2019s test score in all cases had shown improvement but statistically not significant and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value were 0.09, 0.07, and 0.07 respectively. In mild, moderate and severe Rose Bengal staining statistically significant improvement (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value -0.027, 0.0001, and 0.04) .The only side effect was dysgeusia (10% patients).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Rebamipide 2% ophthalmic suspension showed significant improvement in symptoms and signs of dry eye. It able to modify epithelial cell function, improve tear stability, and suppress inflammation suggests that it may be a first drug of choice for severe dry eye disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_2586_22","type":"journal-article","created":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T11:10:52Z","timestamp":1680952252000},"page":"1598-1602","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre"],"prefix":"10.4103","volume":"71","author":[{"given":"Kalpna","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Sardar Patel Medical College, Bikaner, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenu","family":"Jaju","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sardar Patel Medical College, Bikaner, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Sardar Patel Medical College, Bikaner, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajo.2006.11.060","article-title":"Impact of dry eye syndrome on vision-related quality of life","volume":"143","author":"Miljanovi\u0107","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1542-0124(12)70081-2","article-title":"The definition and classification of dry eye disease: Report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007)","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"R3-20240828","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0002-9394(03)00218-6","article-title":"Prevalence of dry eye syndrome among US women","volume":"136","author":"Schaumberg","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R4-20240828","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/0301-4738.16170","article-title":"Dry Eye: Prevalence and attributable risk factors in a hospital based population","volume":"53","author":"Sahai","year":"2005","journal-title":"Indian J Ophthalmol"},{"key":"R5-20240828","first-page":"789","article-title":"Prevalence of dry eye diseases in hospital-based population in West Bengal, Eastern India","volume":"110","author":"Basak","year":"2012","journal-title":"J Indian Med Assoc"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2147\/OPTH.S40798","article-title":"Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: A critical appraisal","volume":"8","author":"Kashima","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"R8-20240828","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1476-9255-6-21","article-title":"Is inflammation a consequence of extracellular hyperosmolarity?","volume":"6","author":"Schwartz","year":"2009","journal-title":"J Inflamm (Lond)"},{"key":"R9-20240828","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/02713683.2013.834939","article-title":"Regulation of human corneal epithelial mucins by rebamipide","volume":"39","author":"Itoh","year":"2014","journal-title":"Curr Eye Res"},{"key":"R10-20240828","first-page":"1004","article-title":"Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sj\u00f6gren syndrome","volume":"43","author":"Arg\u00fceso","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1089\/jop.2011.0147","article-title":"Rebamipide increases mucin-like substance contents and periodic acid Schiff reagent-positive cells density in normal rabbits","volume":"28","author":"Urashima","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/sj.eye.6702873","article-title":"Impression cytology with scanning electron microscopy: A new method in the study of conjunctival microvilli","volume":"22","author":"Cennamo","year":"2008","journal-title":"Eye (Lond)"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1179\/136485910X12647085215859","article-title":"Estimating the prevalence of dry eye among Indian patients attending a tertiary ophthalmology clinic","volume":"104","author":"Gupta","year":"2010","journal-title":"Ann Trop Med Parasitol"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1001\/archopht.118.9.1264","article-title":"Prevalence of and risk factors for dry eye syndrome","volume":"118","author":"Moss","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R15-20240828","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0161-6420(97)30125-0","article-title":"Relation between signs and symptoms of dry eye in the elderly. A population-based perspective","volume":"104","author":"Schein","year":"1997","journal-title":"Ophthalmology"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12886-016-0364-4","article-title":"Smartphone use is a risk factor for pediatric dry eye disease according to region and age: A case control study","volume":"16","author":"Moon","year":"2016","journal-title":"BMC Ophthalmol"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/02713683.2010.544442","article-title":"Blink rate, blink amplitude, and tear film integrity during dynamic visual display terminal tasks","volume":"36","author":"Cardona","year":"2011","journal-title":"Curr Eye Res"},{"key":"R18-20240828","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the ocular surface disease index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R19-20240828","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1272\/jnms.82.229","article-title":"Improvements in signs and symptoms of dry eye after instillation of 2% Rebamipide","volume":"82","author":"Igarashi","year":"2015","journal-title":"J Nippon Med Sch"},{"key":"R20-20240828","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/ICO.0b013e318294f97e","article-title":"Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye","volume":"32","author":"Koh","year":"2013","journal-title":"Cornea"},{"key":"R21-20240828","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.ophtha.2012.06.052","article-title":"Rebamipide (OPC-12759) in the treatment of dry eye: A randomized, double-masked, multicenter, placebo-controlled phase II study","volume":"119","author":"Kinoshita","year":"2012","journal-title":"Ophthalmology"},{"key":"R22-20240828","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12886-015-0040-0","article-title":"Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye","volume":"15","author":"Ueda","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"R23-20240828","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ophtha.2012.12.022","article-title":"A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye","volume":"120","author":"Kinoshita","year":"2013","journal-title":"Ophthalmology"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2586_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:26:37Z","timestamp":1786724797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2586_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2586_22","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"2022-10-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}